Scholars / UChicago Scholar
Tomas Philipson
Professor Emeritus, Harris Public Policy
Tomas J. Philipson is the Daniel Levin Professor of Public Policy Studies at the University of Chicago Harris School of Public Policy and a director of the Health Economics Program of the Becker Friedman Institute at the University. He is also an associate member of the Department of Economics and a former senior lecturer at the Law School. His research focuses on health economics, and he teaches master's and PhD courses in microeconomics and health economics...
Related Working Papers
- Sep 14, 2021The Evidence Base on the Impact of Price Controls on Medical Innovation
- Sep 17, 2017Adjusting Measures of Economic Output for Health: Is the Business Cycle Countercyclical?
- Apr 1, 2017Sharing R&D Risk in Healthcare via FDA Hedges
- Dec 1, 2016How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations
- Feb 1, 2016Labor Markets in Statistics: The Subject Supply Effect in Medical R&D
- Jul 1, 2015Health Care Adherence and Personalized Medicine
- Jan 1, 2010Terminal Care and the Value of Life Near Its End
1 of 1
Related News
- Nov 2, 2022Fed likely to deliver another huge interest rate hike as high inflation persists
- Oct 31, 2022Obamacare open enrollment 2023: What to know
- Oct 31, 2022Economy, inflation remain top voter concerns ahead of midterm elections
- Oct 27, 2022An increase in Q3 real GDP will still not impact the Fed’s monetary policies
- Oct 27, 2022‘Borrowers are feeling the squeeze’ as interest rates climb while inflation remains high, chief financial analyst says
- Oct 14, 2022Democrats need an economic message for swing voters, says former Sen. Heitkamp
- Sep 23, 2022Inflation and higher rates are a ‘dangerous mix’ for consumers already stretched thin, says chief financial analyst
- Sep 21, 2022Friendly Fire From Biden in the War on Cancer
- Sep 15, 2022Subsidies Only Feed Inflation
- Sep 5, 2022Economists are divided on the risk of a U.S. recession. And the jobs data isn’t helping
- Aug 24, 2022New drug pricing law puts cancer drugs in the spotlight
- Aug 10, 2022Gas is cheaper but groceries are not: How to save as food inflation jumps at the fastest pace since 1979
- Aug 8, 2022Better Solutions For Rx Problems
- Jul 19, 2022Here’s What’s Wrong With BBB Lite
- Jul 12, 2022Larry Kudlow: We’re on the front end of recession
- Jun 28, 2022The Economics of Obesity
- Jun 5, 2022College graduates need these 10 ‘inflation-proof’ career and money tips now
- Apr 13, 2022Wholesale prices surge 11.2% in March, highest level on record
- Mar 26, 2022With the US dollar’s dominance in question, here’s how China’s yuan could become a global reserve currency — and why it wouldn’t be all bad
- Mar 15, 2022A rising China and progressive policies endanger US pharmaceutical innovation
- Feb 22, 2022U.S. policies on Russia creating ‘double whammy’ for markets: Economist
- Feb 4, 2022Democrats’ China competition bill hurts American small businesses, Luetkemeyer warns
- Jan 28, 2022Labor costs ‘all about inflation expectations,’ economist says
- Jan 19, 2022An Economic Evaluation of Covid Lockdowns
- Dec 17, 2021We Won’t End AIDS Through Price Controls
- Dec 13, 2021The Fed could tweak monetary policy based on Build Back Better passage, economist says
- Dec 8, 2021Don’t Destroy Future Drug Development
- Oct 6, 2021Op-ed: Now is a bad time to sacrifice medical progress for government pricing
- Jul 27, 2021The Limits of Government Disease Control | Opinion
- Jun 10, 2021College Subsidies Are a Feedback Loop for Bigger Government
- Jan 14, 2021Should Double Charging Patients for Medication be Legal? | Opinion
- Jan 3, 2021How Government Subsidized the Opioid Crisis
- Sep 25, 2020Former acting CEA chair on what lawmakers can learn from the CARES Act
- Sep 11, 2020A Scientific Approach to Evaluating COVID Policy
- Sep 9, 2020Ignore Empty Words: Does Socialism Pass the Market Test? | Opinion
1 of 1